PCOL Exam Questions And Accurate Answers
Drug Y will exhibit lesser therapeutic effect-ANSWER A patient is maintained on
medication with Drug X, which is known to be an enzyme inducer. Later on, Drug Y was
added to his therapeutic regimen. Which of the following can be expected?
A. Drug X will decrease the Vd of Drug Y
B. Drug Y will exhibit longer t1/2
C. Drug X will increase the protein binding of Drug Y
D. The therapeutic effect of Drug Y will decrease E. None of the above
Pharmacodynamics - ANSWER the study of the action of drugs within the body
Pharmacokinetics - ANSWER body to drug
toxicology - ANSWER the study of the poisonous effects of drugs
psology - ANSWER dose study
inducer - ANSWER increases metabolism, fast excretion of drugs, LOWER half-life,
lower therapeutic effect
inhibitor - ANSWER decrease metabolism, slow to none excretion, HIGHER half life,
higher therapeutic effect BUT TOXIC
Typical Antipsychotic - ANSWER act on DOPAMINERGIC system; blocks dopamine type
2 receptors
Atypical Antipsychotic - ANSWER act on SEROTONERGIC; particularly in 5-HT2A
(serotonin); lower affinity for dopaminergic receptors
, TRAP - ANSWER Parkinsons symptoms
Chlorpropamide - ANSWER Sulfonylurea with longest half-life; risk of hypoglycemia
N-acetyltransferase - ANSWER metabolism of HIPS is dependent on this phase II
enzyme
Acetylation - ANSWER HIPS are metabolized through
Alpha 2 - ANSWER adrenergic receptor exerts its action via inhibition of cAMP
production thru inhibition of adenylyl cyclase activity
Gs - ANSWER stimulates
Gi - ANSWER inhibits adenylate cyclase; inhibit conversion of ATP to cAMP
Gq - ANSWER increased IP3 and DAG (q as qontraction)
Nn & Nm - ANSWER ligand-gated Na channels
Hemicholinium - ANSWER inhibit reuptake of choline NOT storage
Vesamicol - ANSWER drug which acts on VESICULAR STORAGE of ACH
Sumatriptan - ANSWER serotonin agonist is best prescribed for relieve the symptom of
migraine
Triptans (5-HT B/D) - ANSWER Migraine
Drug Y will exhibit lesser therapeutic effect-ANSWER A patient is maintained on
medication with Drug X, which is known to be an enzyme inducer. Later on, Drug Y was
added to his therapeutic regimen. Which of the following can be expected?
A. Drug X will decrease the Vd of Drug Y
B. Drug Y will exhibit longer t1/2
C. Drug X will increase the protein binding of Drug Y
D. The therapeutic effect of Drug Y will decrease E. None of the above
Pharmacodynamics - ANSWER the study of the action of drugs within the body
Pharmacokinetics - ANSWER body to drug
toxicology - ANSWER the study of the poisonous effects of drugs
psology - ANSWER dose study
inducer - ANSWER increases metabolism, fast excretion of drugs, LOWER half-life,
lower therapeutic effect
inhibitor - ANSWER decrease metabolism, slow to none excretion, HIGHER half life,
higher therapeutic effect BUT TOXIC
Typical Antipsychotic - ANSWER act on DOPAMINERGIC system; blocks dopamine type
2 receptors
Atypical Antipsychotic - ANSWER act on SEROTONERGIC; particularly in 5-HT2A
(serotonin); lower affinity for dopaminergic receptors
, TRAP - ANSWER Parkinsons symptoms
Chlorpropamide - ANSWER Sulfonylurea with longest half-life; risk of hypoglycemia
N-acetyltransferase - ANSWER metabolism of HIPS is dependent on this phase II
enzyme
Acetylation - ANSWER HIPS are metabolized through
Alpha 2 - ANSWER adrenergic receptor exerts its action via inhibition of cAMP
production thru inhibition of adenylyl cyclase activity
Gs - ANSWER stimulates
Gi - ANSWER inhibits adenylate cyclase; inhibit conversion of ATP to cAMP
Gq - ANSWER increased IP3 and DAG (q as qontraction)
Nn & Nm - ANSWER ligand-gated Na channels
Hemicholinium - ANSWER inhibit reuptake of choline NOT storage
Vesamicol - ANSWER drug which acts on VESICULAR STORAGE of ACH
Sumatriptan - ANSWER serotonin agonist is best prescribed for relieve the symptom of
migraine
Triptans (5-HT B/D) - ANSWER Migraine
